IP Library Granted Patent US 9,144,650
Granted Patent B2
US 9,144,650 · App. 14/040,277 · Granted Sep 29, 2015

Aerosolization device

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,144,650
App. No.
14/040,277
Granted
Sep 29, 2015
Kind
B2
Abstract

An aerosol transfer device for medical aerosol generators includes a body, fluidically coupled to a nebulizer and to a patient interface. An ambient air intake is formed into a lower body. The body is shaped and configured to optimize mixing of ambient air from the ambient air intake and the aerosol generated by the nebulizer, resulting in the formation of an aerosol plume having optimum characteristics for delivery of the aerosol to the patient's pulmonary system, such as the central or deep lung regions. The shape and dimensions of the body are further designed to minimize aerosol deposition, thus improving delivery efficiency.

Claims (13)

1. A method of administering a medicament to a patient, the method comprising

inhaling a dose of an aerosolized medicament by the patient, wherein said dose of the aerosolized medicament is provided by

an aerosol accumulation chamber having a central vertical axis, an upper end and a lower end, the chamber having a major dimension of at least 10 cm, the upper end comprising a nebulizer port and a patient interface port, the lower end comprising an air inlet port, wherein the air inlet port is oriented to be non-aligned with said central vertical axis, said air inlet port further comprising a valve, an outer shell, substantially surrounding the at least said lower end of the aerosol accumulation chamber, the outer shell having one or more air inlet passages about a periphery thereof wherein said one or more air inlet passages is above said air inlet port, said patient interface port fluidically coupled to a patient interface device, and an aerosolized exhaust port intermediate to said patient interface device and to said patient interface port;

a vibrating mesh nebulizer that is fluidically coupled to said nebulizer port; and

a liquid medicament for aerosolization to generate said dose of the aerosolized medicament via the vibrating mesh nebulizer,

wherein said liquid medicament comprises at least one of amikacin, vancomycin and pharmaceutically acceptable salt forms of either of the foregoing.

2. The method of claim 1 , wherein said dose is inhaled within one to four minutes.

3. The method of claim 2 , wherein said dose is inhaled within one minute.

4. The method of claim 1 , wherein said liquid medicament comprises an aqueous solution.

5. The method of claim 4 , wherein said liquid medicament is preservative-free.

6. The method of claim 1 , wherein said liquid medicament comprises amikacin sulfate.

7. The method of claim 1 , wherein the liquid medicament comprises amikacin.

8. The method of claim 1 , wherein said liquid medicament comprises vancomycin.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL 31838, FRAME 0343 Recorded Oct 14, 2015
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 036876/0138 →
GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Oct 6, 2015
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS COLLATERAL AGENT
Reel/Frame 036796/0562 →
SECURITY AGREEMENT Recorded Dec 18, 2013
From: NEKTAR THERAPEUTICS
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 031838/0343 →